Selected Publications

Full List on PubMed

Evaluation of the SSTR2-targeted Radiopharmaceutical 177Lu-DOTATATE and SSTR2-specific 68Ga-DOTATATE PET as Imaging Biomarker in Patients with Intracranial Meningioma. Kurz SC, Zan E, Cordova C, Troxel AB, Barbaro M, Silverman JS, Snuderl M, Zagzag D, Kondziolka D, Golfinos JG, Chi AS, Sulman EP. Clin Cancer Res. 2024 Feb 16;30(4):680-686. doi: 10.1158/1078-0432.CCR-23-2533. PMID: 38048045
Lineage-coupled clonal capture identifies clonal evolution mechanisms and vulnerabilities of BRAFV600E inhibition resistance in melanoma. Zhang ZY, Ding Y, Ezhilarasan R, Lhakhang T, Wang Q, Yang J, Modrek AS, Zhang H, Tsirigos A, Futreal A, Draetta GF, Verhaak RGW, Sulman EP. Cell Discov. 2022 Oct 6;8(1):102. doi: 10.1038/s41421-022-00462-7. PMID: 36202798
PDPN marks a subset of aggressive and radiation-resistant glioblastoma cells. Modrek AS, Eskilsson E, Ezhilarasan R, Wang Q, Goodman LD, Ding Y, Zhang ZY, Bhat KPL, Le TT, Barthel FP, Tang M, Yang J, Long L, Gumin J, Lang FF, Verhaak RGW, Aldape KD, Sulman EP. Front Oncol. 2022 Aug 10;12:941657. doi: 10.3389/fonc.2022.941657. eCollection 2022. PMID: 36059614
DNA methylation-based epigenetic signatures predict somatic genomic alterations in gliomas. Yang J, Wang Q, Zhang ZY, Long L, Ezhilarasan R, Karp JM, Tsirigos A, Snuderl M, Wiestler B, Wick W, Miao Y, Huse JT, Sulman EP. Nat Commun. 2022 Jul 29;13(1):4410. doi: 10.1038/s41467-022-31827-x. PMID: 35906213
Risk of Second Primary Neoplasms of the Central Nervous System. Liu EK, Oh C, Kondziolka D, Sulman EP. Adv Radiat Oncol. 2022 Apr 18;7(4):100969. doi: 10.1016/j.adro.2022.100969. eCollection 2022 Jul-Aug. PMID: 35814854
Melanoma brain metastases harboring BRAF V600K or NRAS mutations are associated with an increased local failure rate following conventional therapy. Fang P, Boehling NS, Koay EJ, Bucheit AD, Jakob JA, Settle SH, Brown PD, Davies MA, Sulman EP. J Neurooncol. 2018 Mar;137(1):67-75. doi: 10.1007/s11060-017-2695-2. Epub 2017 Dec 2. PMID: 29198052
A relative increase in circulating platelets following chemoradiation predicts for poor survival of patients with glioblastoma. Boonyawan K, Hess KR, Yang J, Long L, Wang Q, Ezhilarasan R, Auia A, Alfaro-Munoz KD, de Groot JF, Bhat KP, Sulman EP. Oncotarget. 2017 Oct 12;8(52):90488-90495. doi: 10.18632/oncotarget.21799. eCollection 2017 Oct 27. PMID: 29163847
Tumor Evolution of Glioma-Intrinsic Gene Expression Subtypes Associates with Immunological Changes in the Microenvironment. Wang Q, Hu B, Hu X, Kim H, Squatrito M, Scarpace L, deCarvalho AC, Lyu S, Li P, Li Y, Barthel F, Cho HJ, Lin YH, Satani N, Martinez-Ledesma E, Zheng S, Chang E, Sauvé CG, Olar A, Lan ZD, Finocchiaro G, Phillips JJ, Berger MS, Gabrusiewicz KR, Wang G, Eskilsson E, Hu J, Mikkelsen T, DePinho RA, Muller F, Heimberger AB, Sulman EP*, Nam DH*, Verhaak RGW*. (* equal contribution, co-corresponding) Cancer Cell. 2017 Jul 10;32(1):42-56.e6. doi: 10.1016/j.ccell.2017.06.003. PMID: 28697342
Mesenchymal differentiation mediated by NF-κB promotes radiation resistance in glioblastoma. Bhat KPL, Balasubramaniyan V, Vaillant B, Ezhilarasan R, Hummelink K, Hollingsworth F, Wani K, Heathcock L, James JD, Goodman LD, Conroy S, Long L, Lelic N, Wang S, Gumin J, Raj D, Kodama Y, Raghunathan A, Olar A, Joshi K, Pelloski CE, Heimberger A, Kim SH, Cahill DP, Rao G, Den Dunnen WFA, Boddeke HWGM, Phillips HS, Nakano I, Lang FF, Colman H, Sulman EP*, Aldape K*. (* equal contribution, co-corresponding) Cancer Cell. 2013 Sep 9;24(3):331-46. doi: 10.1016/j.ccr.2013.08.001. Epub 2013 Aug 29. PMID: 23993863

Page updated

Google Sites

Report abuse